Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung

BACKGROUND: Lutathera is a (177)Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibody, may act synergistically with lutathera to g...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chul, Liu, Stephen V, Subramaniam, Deepa S, Torres, Tisdrey, Loda, Massimo, Esposito, Giuseppe, Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333915/
https://www.ncbi.nlm.nih.gov/pubmed/32616557
http://dx.doi.org/10.1136/jitc-2020-000980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333915/
https://www.ncbi.nlm.nih.gov/pubmed/32616557
http://dx.doi.org/10.1136/jitc-2020-000980

Ejemplares similares